APGE APOGEE THERAPEUTICS INC

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

Apogee Therapeutics to Participate in Upcoming November Investor Conferences

SAN FRANCISCO and WALTHAM, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, asthma, chronic obstructive pulmonary disease and other inflammatory and immunology indications, today announced that management will present at the following upcoming investor conferences:

Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference

Date: Monday, November 6, 2023

Time: 2:30 p.m. ET

Stifel 2023 Healthcare Conference

Date: Tuesday, November 14, 2023

Time: 10:20 a.m. ET

Jefferies London Healthcare Conference

Date: Wednesday, November 15, 2023

Time: 11:30 a.m. ET

Evercore ISI 6th Annual HealthCONx Conference

Date: Tuesday, November 28, 2023

Time: 11:15 a.m. ET

A live and archived webcast of the fireside chats and presentations will be available via the page in the Investors section of the Apogee Therapeutics website.

About Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit .

Investor Contacts:

Noel Kurdi

VP of Investor Relations

Apogee Therapeutics

Bill Slattery

THRUST Strategic Communications

Media Contact:

Dan Budwick 1AB Media



EN
30/10/2023

Underlying

APGEAPOGEE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APOGEE THERAPEUTICS INC

Wedbush Research
  • Wedbush Research
W WAYFAIR INC.
SHOP SHOPIFY INC.
WDC WESTERN DIGITAL CORPORATION
TRIP TRIPADVISOR INC.
STAA STAAR SURGICAL CO.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BBY BEST BUY CO. INC.
AXTI AXT INC.
2303 UNITED MICROELECTRONICS CORP.
CVNA CARVANA CO. CLASS A
ANAB ANAPTYSBIO INC.
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
PASG INC.
BEAM PASSAGE BIO
DASH BEAM THERAPEUTICS
ABNB DOORDASH
PLTR AIRBNB INC. CLASS A
IMNM PALANTIR TECHNOLOGIES
SANA IMMUNOME
XMTR SANA BIOTECHNOLOGY
STX XOMETRY
TTD INC.
GFS SEAGATE TECHNOLOGY HLDGS PLC
MLTX THE TRADE DESK
PRME INC.
APGE GLOBALFOUNDRIES INC
CART MOONLAKE IMMUNOTHERAPEUTICS
IMA PRIME MEDICINE INC
VOYG APOGEE THERAPEUTICS INC
MAPLEBEAR INC.
IMAGENEBIO INC.
VOYAGER TECHNOLOGIES INC
03/04/26 March 4, 2026 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
APGE APOGEE THERAPEUTICS INC
IMA IMAGENEBIO INC.
03/03/26 March 3, 2026 1 EN
Wedbush Research
  • Wedbush Research
WDC WESTERN DIGITAL CORPORATION
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
LRMR INC.
NUVB LARIMAR THERAPEUTICS INC
STX NUVATION BIO INC (A)
QUBT SEAGATE TECHNOLOGY HLDGS PLC
GFS QUANTUM COMPUTING INC
S GLOBALFOUNDRIES INC
RGTI SENTINELONE INC
TYRA RIGETTI COMPUTING INC
APGE TYRA BIOSCIENCES INC
NATL APOGEE THERAPEUTICS INC
RBRK NCR ATLEOS CORPORATION
RUBRIK INC
03/03/26 March 3, 2026 1 EN
 PRESS RELEASE
Free
APGE APOGEE THERAPEU...

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2...

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data expected this month- APEX Phase 2 Part B 16-week data expected in Q2 2026- Phase 3 trial initiation in AD anticipated in 2H 2026- Successful expansion of zumilokibart beyond AD demonstrated in asthma Phase 1b trial; details on asthma and eosinophilic esophagitis (EoE) trials expected later this year Phase 1b head-to-head trial of APG279 (zumiloki...

March 2, 2026 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
APGE APOGEE THERAPEUTICS INC
03/02/26 March 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch